Sofpromed Revenue and Competitors
Estimated Revenue & Valuation
- Sofpromed's estimated annual revenue is currently $8.8M per year.
- Sofpromed's estimated revenue per employee is $201,000
Employee Data
- Sofpromed has 44 Employees.
Sofpromed's People
Name | Title | Email/Phone |
---|
Sofpromed Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $88M | 315 | -3% | N/A | N/A |
#2 | $701.5M | 3383 | 3% | $20M | N/A |
#3 | $5.6M | 48 | N/A | N/A | N/A |
#4 | $4.1M | 37 | -20% | $950K | N/A |
#5 | $1.7M | 23 | 0% | $30M | N/A |
#6 | $0.7M | 9 | N/A | N/A | N/A |
#7 | $0.7M | 9 | N/A | N/A | N/A |
#8 | $0.6M | 8 | N/A | N/A | N/A |
#9 | $2.6M | 26 | N/A | N/A | N/A |
#10 | $14.8M | 102 | N/A | N/A | N/A |
#11 | $5060M | 9287 | -20% | $6.9M | $22.5B |
#12 | $56.4M | 317 | 7% | $8M | N/A |
#13 | $3.9M | 34 | N/A | N/A | N/A |
#14 | $5M | 25 | N/A | N/A | N/A |
#15 | $7.8M | 60 | 30% | N/A | N/A |
#16 | $26.6M | 167 | N/A | N/A | N/A |
#17 | $1412M | 7025 | N/A | N/A | N/A |
#18 | $19.9M | 99 | N/A | N/A | N/A |
#19 | $15.7M | 107 | 23% | $17.2M | N/A |
#20 | $7.1M | 51 | N/A | N/A | N/A |
What Is Sofpromed?
N/A
Total Funding
44
Number of Employees
$8.8M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sofpromed News
2022-04-17 - Phase I IV Clinical Development Services Market Analysis 2022 to ...
... Inc., Synteract, ICBio CRO, Sofpromed, Profil, ICON Plc, Clinipace, OCT Clinical, EPS Group, Beijing Sun-novo Pharmaceutical Research,...
2022-04-06 - Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Thus, according to an estimate by Sofpromed, the average cost of a Phase 1 clinical trial for eventual approval by the U.S. Food and Drug...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.1M | 44 | N/A | N/A |
#2 | $9.1M | 45 | 36% | N/A |
#3 | $7.3M | 51 | 38% | N/A |
#4 | $7.8M | 54 | 6% | $9M |
#5 | $13.7M | 60 | 20% | N/A |